GENB
Generate Biomedicines, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 27 ▼ Generate Biomedicines is pricing its IPO of 25 million shares at $16…
- Mar 2 to Mar 4 ▲ 2 days of insider buys: $50.3M by 5 insiders, avg $15.97
- Mar 2 ▲ Generate Biomedicines CEO Michael Nally led a $240,000 open-market s…
- May 7 ▼ Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2…
- Sep 1 ▼ 1 insider sell $16.0K at $16.00
- Oct 1 FDA: Roswell Park, Generate Biomedicines Launch Exclusive Clini…
- Oct 13 ▲ Generate Biomedicines announced a multi-target collaboration with Ze…
- Oct 13 Contract: Generate Biomedicines and Zealand Pharma Enter Collaborati…
- Oct 29 ▼ 1 insider sell $184.7K at $16.19
- Nov 12 ▼ Earnings: GENB Q3 2026 Earnings: EPS $-0.68 (-19.8% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
5 insiders bought $50.3M at an average $15.97. 1 insider sold $200.7K. Price is 24% below their cost.
- InstitutionsBULLISH
Q3 2026: 16 added (1 new), 3 trimmed or exited. Largest new: Banque Pictet & Cie Sa $26.6M.
- AnalystsBULLISH
11 of 12 rate it Buy or better.
- Short sellersSTEADY
Short interest +1.7% to 9.08M shares. 8.9 days to cover, ≈7.1% of shares.
- TrendDOWNTREND
16% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $107.9M |
| JPMORGAN CHASE & CO | ADD | $40.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $33.6M |
| ARK Investment Management LLC | ADD | $29.5M |
| BANQUE PICTET & CIE SA | NEW | $26.6M |
| MORGAN STANLEY | ADD | $7.8M |
| TD ASSET MANAGEMENT INC | DOUBLED | $2.8M |
| ALPS ADVISORS INC | ADD | $2.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 8, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 28, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ARNOLD FRANCES Director Oct 29, 2026 | SELL | $184.7K |
ARNOLD FRANCES Director Sep 1, 2026 | SELL | $16.0K |
Nally Michael Chief Executive Officer Mar 4, 2026 | BUY | $240.0K |
AFEYAN NOUBAR Director Mar 2, 2026 | CONVERT | 18,483,785 sh |
AFEYAN NOUBAR Director Mar 2, 2026 | CONVERT | 2,109,704 sh |
Grous Beth Chief People Officer Mar 2, 2026 | BUY | $4.8K |
Nally Michael Chief Executive Officer Mar 2, 2026 | CONVERT | 658,327 sh |
AFEYAN NOUBAR Director Mar 2, 2026 | CONVERT | 18,483,785 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 2 press releases · 1 bullish · 3 bearish · 5 neutral- BEARISH 8-KNov 12, 2026
Generate Biomedicines reported Q3 2026 collaboration revenue of $4.2M (down 56% YoY from $9.6M)…
The revenue decline reflects near-completion of Amgen and Novartis collaboration obligations, creating a revenue gap. Watch for new partnership announcements to replace this revenue stream and for…
- NEUTRAL SC 13GNov 5, 2026
FMR LLC (Fidelity) filed a Schedule 13G disclosing a 5.6% passive stake in Generate Biomedicines…
Fidelity's passive 5.6% stake is a routine institutional holding for a mid-cap biotech. Monitor future 13G amendments for stake increases or a conversion to 13D if Fidelity engages with management…
- NEUTRAL INST-CLUSTERNov 3, 2026
Three institutional asset managers increased their positions in Generate Biomedicines during Q3…
The cluster is dominated by a single new $26.6M position from Banque Pictet & Cie, which accounts for 87% of the net buying. With no insider buying and a low confluence score, the signal is weak…
- NEUTRAL 144Oct 29, 2026
Director Frances Arnold filed a Form 144 notice to sell 11,409 shares of Generate Biomedicines…
The sale is small relative to market cap and appears to be a routine diversification move by a director. Monitor for actual execution on Form 4; no immediate concern given the modest size and lack…
All GENB filing & press-release reports (11)
- 8-K reportNov 12, 2026
- SC 13G reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- 144 reportOct 29, 2026
- PRESS-RELEASE reportOct 13, 2026
- PRESS-RELEASE reportOct 1, 2026
- 8-K reportMay 7, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026
- 424B4 reportFeb 27, 2026
- EFFECT reportFeb 27, 2026